Summary:
- FDA approves antipsychotic drug for use in treating mental illness and Alzheimer’s
- Drug developed by Karuna Therapeutics, acquired by Bristol Myers Squibb
- Approval comes less than a year after acquisition
- Drug offers new option for patients with these conditions